Literature DB >> 26001871

Performance measures related to colposcopy for canadian cervical cancer screening programs: identifying areas for improvement.

Kathleen M Decker1, C Meg McLachlin2, Robert Lotocki3.   

Abstract

OBJECTIVE: To describe performance measures related to colposcopic examinations in Canadian cervical cancer screening programs; specifically, time to colposcopy, histological investigation rate, and agreement between cytology and histology.
METHODS: As part of a national report on the performance of cervical cancer screening, aggregate provincial cervical cancer screening data provided by provinces to the Pan-Canadian Cervical Screening Network were used to evaluate colposcopy program performance measures for women 20 to 69 years of age who had a Pap test in 2009 and 2010.
RESULTS: A total of 37 523 women had a high-grade or more severe Pap test result. The proportion of women who had a colposcopy ≤ 90 days after their Pap test ranged from 30.9% to 51.5%. Fewer women 60 to 69 years of age had a colposcopy than women in younger age groups. The proportion of women who had a high-grade or more severe Pap test result and colposcopy who had a biopsy within 12 months ranged from 82.1% to 96.5%. The proportion of biopsy results that agreed with the Pap test result ranged from 59.5% to 82.1%.
CONCLUSION: The time from having a high-grade Pap test result to undergoing colposcopy must be reduced to lower the risk of adverse outcomes and the stress associated with delayed follow-up. The agreement between screening cytology and histology meets the national target of ≥ 65%. Although six of 13 provinces and territories provided data for colposcopy-related performance measures, more information is needed to assess colposcopy services accurately at the national level.

Entities:  

Keywords:  cervical cancer; cervical cytology; colposcopy; screening

Mesh:

Year:  2015        PMID: 26001871     DOI: 10.1016/S1701-2163(15)30310-8

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  2 in total

1.  Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials.

Authors:  Jean-Luc Brun; José Rajaonarison; Nicolas Nocart; Laura Hoarau; Stéphanie Brun; Isabelle Garrigue
Journal:  Mol Clin Oncol       Date:  2017-12-08

2.  Measuring colposcopy quality in Canada: development of population-based indicators.

Authors:  K Decker; N Baines; C Muzyka; M Lee; M H Mayrand; H Yang; S Fung; D Mercer; S McFaul; R Kupets; R Savoie; R Lotocki; J Bentley
Journal:  Curr Oncol       Date:  2019-06-01       Impact factor: 3.677

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.